Comparison of the mechanisms of action of antidepressants and their side effects

Magdalena Wasielewska



Introduction: There are 4 groups of LPs divided according to the mechanism of action. They act on the brain by modulating monoaminergic systems, causing a series of side effects such as insomnia, sedation, anxiety, and a problem of a sexual nature. By appropriately selecting the drug and its dose, the negative effects of the therapy can be avoided.

Aim : Comparison of the mode of action of a drug from a given group of antidepressants and description of its side effects.

State of knowledge : An example from the first group of drugs with a receptor mechanism of action is trazodone - it acts on many receptors. The combined effect of the drug on all three receptors will significantly improve sleep in all its phases. It is as effective a drug as TLPD, and due to the lack of anticholinergic and cardiotoxic effects, it has a better tolerance and safety profile. It works quickly and improves sleep parameters, which is responsible for faster improvement of the patient's mental state. An example of a drug from the second group of drugs with a different mechanism of action is agomelatine. It is a synthetic analog of melatonin. The simultaneous agonist action on one receptors and antagonist action on the other causes a number of changes in the CNS, which are responsible for the antidepressant effect. The effects of the treatment can be seen after 2 weeks of use. The drug of the third groupneurotransmitter reuptake inhibitorsthere is bupropion. It intensifies the dopaminergic transmission. It does not disturb the sexual sphere, but increases insomnia as a side effect.

Summary : By selecting the appropriate LP and its dose, side effects can be avoided.


depression; mental disorders; antidepressants; side effects

Full Text:



Kostowski W. Współczesne kierunki badań nad patomechanizmem stresu i depresji i ich znaczenie w kształtowaniu poglądów na działanie leków przeciwdepresyjnych. Psychiatria, 2004; 2 (1): 63-71. (13.08.2020)

Burke MJ, Preskorn SEE. Short-term treatment of mood disorders with standard antidepressants. W: Bloom FE, Kupfer DJ, red, Psychopharmacology: The fourth generation of Progress. New York: Raven Press; 1995, s. 1053-1065.

Riblet LA, Taylor DP. Pharmacology and neurochemistry of trazodon. J. Clin. Psychopharmacol. 1981; 1 (supl): 17-22.

Stahl SM. Mechanism of action of trazodon: a multifunctional drug. CNS Spectr. 2009; 14: 536-546.

Oberndorfer S, Saletu-Zychlarz G, Saletu B. Effects of selective serotonin reuptake inhibitors on objective and subjective sleep quality. Neuropsychobiol. 2000; 42: 69-81.

Le Bon O. Contribution of sleep research to the development of New antidepressant. Dialog. Clin. Neurosc. 2005; 7: 305-313.

Shigemoto Y, Fujii Y, Shinomiya K, Kamei C. Participation of histaminergic H1 and noradrenergic alpha 1 receptors in orexin A-induced wakefulness in rats. Brain Res. 2004; 1023: 121-125.

Landowski J. Wybór leku przeciwdepresyjnego. Dysk. Depr. 2001; 10: 2-11.

Stahl SM. Mechanism of action of trazodon: a multifunctional drug. CNS Spectr. 2009; 14: 536-546.

Monteleone P, Delrio G. Pharmacocinetic and pharmacodynamic characteristics of a controlled release formulation of trazodone versus the conventional formulation in healthy volunteers. Ital. J. Neurol. Sc. 1993; 14: 443-449.

Haria M, Fitton AS, McTavish D. Trazodone. A review of its pharmacology, therapeutics use in depression and therapeutic potential in other disorders. Drugs Aging 1994; 4: 331-335.

Mann J, Georgotas A, Newton R, Gerschon S. A controlled study of trazodone, imipramine and placebo in outpatients with endogenous depression. J. Clin. Psychopharmacol. 1981; 42 (1): 75-80.

Carney PA, Healy D, Leonard BE. A double-blind study to compare trazodone with amitryptyline in depressed patients. The role of trazodone in antidepressant therapy: safety and clinical efficacy. Psychopathol. 1984; 17 (supl. 2): 37-38.

Poldinger W. Experiences with doxepine and trazodone in the therapy with outpatients suffering from depression. Psychopathol. 1984; 17: 30-36.

Cubała W, Landowski J. Spektrum zastosowań klinicznych trazodonu. Psychiatr. 2011; 8: 1-6.

Beasley CM Jr, Dornseif BE, Pultz JA, Bosomworth JC, Sayler ME. Fluoxetin versus trazodone : Efficacy and activating-sedating effects. J. Clin. Psychiatry 1991; 52: 294-299.

Fabre LF Jr. United States experience and perspective with trazodone. Clin. Neuropharmacol. 1989; 12 (supl. 1): 11-17.

Le Strat Y, Gorwood P. Agomelatine, an innovative pharmacological response to unmet needs. J. Psychopharmacol. 2008; 22: 4-8.

Papp M, Litwa, Gruca P, Mocaer E. Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety. Behav. Pharmacol. 2006; 17: 9-18.

Stahl SM. Novel mechanizm of antidepressant action: norepinephrine and dopamine disinhibition (NDDI) plus melatonergic agonism. Int. J. Neuropsychopharmacol. 2007; 10 (5): 575-578.

Millan MJ, Gobert A, Lejeune F i wsp. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activiy of trontocortical dopaminergic and adrenergic pathways. J. Pharmacol. Exp. Ther. 2003; 306: 954-964.

Hanoun N, Mocaer E, Boyer PA, Hamon M, Lanfumey L. Differental effects of the novel antidepressant agomelatine (S20098) versus fluoxetine on 5-HT1A receptors in the rat brain. Neuropharmacology 2004; 47: 515-526.

Zupancic M, Guilleminault C. Agomelatine: a preliminary review of a New antidepressant. CNS Drugs 2006; 20 (12): 981-992.

Gressens P, Schwedimann L, Husson I i wsp. Agomelatine, a melatonin receptor agonist with 5-HT2C receptor antagonist properties, protects the developing murine white matter against excitotoxicity. Eur. J. Pharmacol. 2008, 588: 58-63.

Hale A, Coral RM, Mencacci C, Ruiz JS, Severo CA, Gentil V. Superior

antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, doubleblind study. Int. Clin. Psychopharmacol. 2010, 25: 305-314.

European Medicine Agency: Evaluation of medicines for human use – CHMP Assessment Report for Valdoxan, (6.08.2020)

Stahl SM, Fava M, Trivedi MH, Caputo A, Post A. Agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J. Clin. Psychopharmacol. 2010; 30: 135-144.

Dunlop BW, Nemerhoff CB. The role of dopamine in the pathophysiologiy of depression. Arch. Gen. Psychiatry 2007; 64: 327-337.

Learned-Coughlin SM, Bergstrom M, Savitcheva I, Ascher J, Schmith VD, Langstrom B. In vivo activity of bupropion at the human dopamine transporter as measures by positron emission tomography. Biol. Psychiatry 2003; 53: 800-805.

Panksepp J, Burgdorf J. The neurobiology of positive emotions. Neurosc. Biobehavior Rev. 2006; 30: 173-187.

Angs J. Sexual problems in health and depressed persons. Int. Clin. Psychopharmacol. 1998; (13) 1: 28-35.

Jefferson JW, Pradko JF, Muir KT. Bupropion for major depressive disorder: pharmacokinetic and formulation considerations. Clin. Ther. 2005; 27: 1685-1695.

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM

Journal of Education, Health and Sport formerly Journal of Health Sciences

Declaration on the original version.

Editors indicates that the main version of the magazine is to issue a "electronic".

The journal has had 5 points in Ministry of Science and Higher Education parametric evaluation. § 8. 2) and § 12. 1. 2) 22.02.2019.

1223 Journal of Education, Health and Sport eISSN 2391-8306 7

ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

Archives 2011 - 2014

PBN 2011 - 2014

POL-index 2011 - 2014

BASE 2011 - 2014

Indexed in Bases, Bazy indeksacyjne: ERIH Plus, Worldcat, PBN/POL-Index, ICI Journals Master List, Directory of Open Access Journals (DOAJ), ZBD, Ulrich's periodicals, Google Scholar, Polska Bibliografia Lekarska, EuroPub database, NLM Catalog Result - NCBI, BASE, Russian Sciences Index, Arianta.

US NLM = 101679844

101679844 - NLM Catalog Result - NCBI

Find a library that holds this journal:


PBN Poland



Redaction, Publisher and Editorial Office

Publisher and Editorial Office
Department of Physical Culture,
Faculty of Earth Sciences and Spatial Management,
Nicolaus Copernicus University in Toruń, Poland
Address: Str. Lwowska 1, 87-100 Toruń, Poland

  Open Access ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

The journal has been approved for inclusion in ERIH PLUS.

The ERIH PLUS listing of the journal is available at

Indexed in Index Copernicus Journals Master List.,p24782242,3.html

ICV 2018 = 95.95 ICV 2017 = 91.30 ICV 2016 = 84.69 ICV 2015 = 93.34 ICV 2014 = 89.51 Standardized Value: 8.27 ICV 2013: 7.32 ICV 2012: 6.41 ICV 20115.48

RG Journal Impact: 0.18 *

*This value is calculated using ResearchGate data and is based on average citation counts from work published in this journal. The data used in the calculation may not be exhaustive.

RG Journal impact history

2020Available summer 2021
2018 / 20190.18

RG Journal impact over time

RG Journal impact

Indexed in Polish Scholarly Bibliography (PBN) (PBN Polska Bibliografia Naukowa) (

is a portal of the Polish Ministry of Science and Higher Education, collecting information on publications of Polish scientists and on Polish and foreign scholarly journals. Polish Scholarly Bibliograhpy is a part of POL-on - System of Information on Higher Education. It is operated by the Interdisciplinary Centre for Mathematical and Computational Modelling, University of Warsaw.

Indexed in Russian Sciences Index Российский индекс научного цитирования (РИНЦ)

Indexed in Arianta Polish scientific and professional electronic journals Aneta Drabek i Arkadiusz Pulikowski


Partnerzy platformy czasopism